Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
$37.74
+0.1%
$35.88
$3.03
$49.87
$396.65M2.45795,268 shs500,504 shs
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
$0.19
$0.20
$0.09
$3.59
$10.55M2.172.39 million shs352,721 shs
Indivior PLC stock logo
INVVY
Indivior
$21.85
-1.8%
$21.85
$14.76
$35.50
$3.01B0.353,825 shs8,100 shs
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
$1.73
$1.38
$3.79
$117.93M1.08126,298 shs141,800 shs
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
$6.85
+0.9%
$5.72
$2.86
$7.76
$290.58M1.88158,575 shs86,259 shs
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
-3.92%-11.75%+7.90%+416.44%+326.47%
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
+3.70%+24.79%-18.46%+6.12%-93.16%
Indivior PLC stock logo
INVVY
Indivior
0.00%0.00%0.00%0.00%+0.30%
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
0.00%0.00%0.00%0.00%0.00%
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
-2.72%-1.88%+35.53%+17.07%+4.30%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
4.4921 of 5 stars
3.53.00.04.72.93.30.6
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Indivior PLC stock logo
INVVY
Indivior
N/AN/AN/AN/AN/AN/AN/AN/A
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
3.5837 of 5 stars
3.51.00.04.70.62.50.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
3.00
Buy$52.0037.78% Upside
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
1.75
ReduceN/AN/A
Indivior PLC stock logo
INVVY
Indivior
N/AN/AN/AN/A
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
N/AN/AN/AN/A
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
3.00
Buy$11.2564.23% Upside

Current Analyst Ratings

Latest VRCA, CRBP, REPH, INVVY, and GRTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/10/2024
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
3/13/2024
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$51.00 ➝ $58.00
3/6/2024
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$4.00 ➝ $46.00
3/1/2024
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$12.00 ➝ $13.00
3/1/2024
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
1/29/2024
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$20.00 ➝ $51.00
(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
$880K450.74N/AN/A($1.56) per share-24.19
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
N/AN/AN/AN/A($2.41) per shareN/A
Indivior PLC stock logo
INVVY
Indivior
$791M3.81$1.15 per share18.94$1.45 per share15.07
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
$75.36M0.00N/AN/A$0.90 per share0.00
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
$5.12M56.75N/AN/A$0.47 per share14.57

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
-$44.60M-$10.37N/AN/AN/AN/A-920.31%-111.56%5/14/2024 (Estimated)
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
-$59.08M-$1.41N/AN/AN/AN/A-137.47%5/9/2024 (Estimated)
Indivior PLC stock logo
INVVY
Indivior
$205M$1.0520.8112.00N/AN/AN/AN/AN/A
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
-$11.37M-$0.31N/AN/AN/A-15.15%-56.66%-11.14%N/A
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
-$67M-$1.46N/AN/AN/A-1,307.47%-119.46%-70.35%5/14/2024 (Estimated)

Latest VRCA, CRBP, REPH, INVVY, and GRTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/28/2024Q4 2023
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
N/A-$0.10-$0.10-$0.10N/AN/A
3/12/2024Q4 2023
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
-$2.36-$1.81+$0.55-$1.81N/AN/A
2/29/2024Q4 2023
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
-$0.47-$0.48-$0.01-$0.43$1.10 million$1.99 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
N/AN/AN/AN/AN/A
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
N/AN/AN/AN/AN/A
Indivior PLC stock logo
INVVY
Indivior
N/AN/AN/AN/AN/A
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
N/AN/AN/AN/AN/A
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
N/A
0.74
0.74
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
N/A
4.36
4.36
Indivior PLC stock logo
INVVY
Indivior
N/AN/AN/A
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
2.27
3.24
2.74
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
2.22
4.55
4.49

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
64.64%
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
50.77%
Indivior PLC stock logo
INVVY
Indivior
0.05%
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
62.34%
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
42.45%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
1910.51 million10.09 millionOptionable
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
754.39 million50.64 millionOptionable
Indivior PLC stock logo
INVVY
Indivior
800137.88 millionN/ANot Optionable
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
18556.42 million48.41 millionOptionable
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
10042.42 million24.82 millionOptionable

VRCA, CRBP, REPH, INVVY, and GRTX Headlines

SourceHeadline
Verrica Pharmaceuticals Inc (VRCA)Verrica Pharmaceuticals Inc (VRCA)
investing.com - April 19 at 7:13 PM
Needham & Company LLC Reiterates "Buy" Rating for Verrica Pharmaceuticals (NASDAQ:VRCA)Needham & Company LLC Reiterates "Buy" Rating for Verrica Pharmaceuticals (NASDAQ:VRCA)
marketbeat.com - April 10 at 8:24 AM
Verrica Pharmaceuticals to Spotlight Innovations at Needham Healthcare ConferenceVerrica Pharmaceuticals to Spotlight Innovations at Needham Healthcare Conference
msn.com - April 4 at 11:15 AM
Strong week for Verrica Pharmaceuticals (NASDAQ:VRCA) shareholders doesnt alleviate pain of three-year lossStrong week for Verrica Pharmaceuticals (NASDAQ:VRCA) shareholders doesn't alleviate pain of three-year loss
finance.yahoo.com - April 3 at 8:23 AM
Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare ConferenceVerrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
globenewswire.com - April 2 at 7:30 AM
Verrica Pharmaceuticals Secures Key FDA Designation for YCANTH, Enhancing Market ProtectionVerrica Pharmaceuticals Secures Key FDA Designation for YCANTH, Enhancing Market Protection
msn.com - March 31 at 11:37 AM
Verrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Announces that YCANTH Receives New Chemical Entity Status and Orange Book Listing from the FDAVerrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Announces that YCANTH Receives New Chemical Entity Status and Orange Book Listing from the FDA
finanznachrichten.de - March 28 at 3:45 PM
Verrica Pharma gains as FDA lists Ycanth in Orange BookVerrica Pharma gains as FDA lists Ycanth in Orange Book
msn.com - March 27 at 3:42 AM
Verrica Pharmaceuticals: YCANTH Granted NCE Status By FDA - Quick FactsVerrica Pharmaceuticals: YCANTH Granted NCE Status By FDA - Quick Facts
markets.businessinsider.com - March 26 at 8:15 AM
Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDAVerrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA
globenewswire.com - March 26 at 7:30 AM
Verrica Pharmaceuticals Set to Illuminate TD Cowen Healthcare Conference with Fireside ChatVerrica Pharmaceuticals Set to Illuminate TD Cowen Healthcare Conference with Fireside Chat
msn.com - March 3 at 10:22 PM
Verrica Pharmaceuticals Full Year 2023 Earnings: Revenues Beat Expectations, EPS In LineVerrica Pharmaceuticals Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line
finance.yahoo.com - March 2 at 10:39 AM
When Will Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Become Profitable?When Will Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Become Profitable?
finance.yahoo.com - March 2 at 10:39 AM
Verrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial ResultsVerrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
finanznachrichten.de - March 1 at 11:46 PM
Verrica Pharmaceuticals Outperforms with YCANTH Sales, Promising Outlook Spurs Buy RatingVerrica Pharmaceuticals Outperforms with YCANTH Sales, Promising Outlook Spurs Buy Rating
markets.businessinsider.com - March 1 at 6:46 PM
Buy Rating Affirmed for Verrica Pharmaceuticals Following Strong Ycanth Launch and Strategic Market ExpansionBuy Rating Affirmed for Verrica Pharmaceuticals Following Strong Ycanth Launch and Strategic Market Expansion
markets.businessinsider.com - March 1 at 6:46 PM
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2023 Earnings Call TranscriptVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2023 Earnings Call Transcript
finance.yahoo.com - March 1 at 1:45 PM
Buy Rating Affirmed for Verrica Pharmaceuticals Amidst Promising Ycanth Launch and Market AcceptanceBuy Rating Affirmed for Verrica Pharmaceuticals Amidst Promising Ycanth Launch and Market Acceptance
markets.businessinsider.com - February 29 at 10:09 PM
Verrica Pharmaceuticals Inc (VRCA) Reports Fourth Quarter and Full-Year 2023 Financial ResultsVerrica Pharmaceuticals Inc (VRCA) Reports Fourth Quarter and Full-Year 2023 Financial Results
finance.yahoo.com - February 29 at 12:07 PM
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial ResultsVerrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
globenewswire.com - February 29 at 7:30 AM
Earnings Outlook For Verrica PharmaceuticalsEarnings Outlook For Verrica Pharmaceuticals
benzinga.com - February 28 at 6:01 PM
Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare ConferenceVerrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference
globenewswire.com - February 27 at 7:30 AM
Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024
finance.yahoo.com - February 22 at 10:58 AM
Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024
globenewswire.com - February 22 at 7:30 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Corbus Pharmaceuticals logo

Corbus Pharmaceuticals

NASDAQ:CRBP
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Galera Therapeutics logo

Galera Therapeutics

NASDAQ:GRTX
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also developing GC4711, a dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.
Indivior logo

Indivior

OTCMKTS:INVVY
Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom.
Recro Pharma logo

Recro Pharma

NASDAQ:REPH
Recro Pharma, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The firm offers integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Exton, PA.
Verrica Pharmaceuticals logo

Verrica Pharmaceuticals

NASDAQ:VRCA
Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.